• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio

    Frontage Bolsters Clinical Services Capabilities

    Sanofi Unveils EUROAPI as Name of New European API Company

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Sanofi Unveils EUROAPI as Name of New European API Company

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza

    Fujifilm, CABIM Get $76M Funding for Mfg. and Innovation Center

    LSNE Expands Fill Finish and Lyophilization Ops
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe

    Schreiner MediPharm Joins DoseID Consortium
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Virtual Clinical Trials: The Future of Dermatology Studies

    Frontage Bolsters Clinical Services Capabilities

    Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz

    Precision Medicine Group Acquires Project Farma

    Cytiva Delivers Modular Biologics Factory to Lonza
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics

    The Wasdell Group Earns ISO 13485 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Alcami

    Adare Pharma Solutions

    Flow Sciences

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Emergent BioSolutions

    Alcami

    Adare Pharma Solutions

    Flow Sciences
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Taking Stock of Biopharma’s Outsourcing Markets

    Outsourcing of testing services on the rise

    Related CONTENT
    • Vetio Animal Health
    • Kemwell Provides Services for U.S. Trial
    • Current Trends in Analytical Testing
    • CMOs & Biosimilars Mfg. in the U.S.
    • CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Eric S. Langer, BioPlan Associates03.09.16
    In recent years we have witnessed an expansion of the biopharmaceutical manufacturing outsourcing market, as contract manufacturing organizations (CMOs) have begun actively scouting and integrating new technologies that position themselves as sophisticated partners willing and able to take on high-value activities. Not only are CMOs often the first place innovative technologies are tested, but some mid-tier and larger CMOs have formal programs in place to identify and cultivate new innovations that can enhance the overall services they provide.

    Data from BioPlan Associates’ 13th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production this year indicates that this function as a source of innovation is boosting CMO service providers’ breadth of services as well. In fact, early responses to our study this year indicate that 22 of the 24 outsourcing activities we measured continue to see an uptick in the breadth of outsourcing. In other words, more companies are deciding to outsource a bigger range of services.

    The most commonly outsourced activities were led by:
    • Analytical testing of bioassays (92% outsourcing to some degree this year, up from 86% last year1 and maintaining the top spot);
    • Fill/finish operations (80%, up from 73%);
    • Toxicity testing (75%, up from 72%); and
    • Validation services (73%, relatively flat from last year).

    It’s interesting to see continued growth in the outsourcing of these common activities, suggesting that they have not yet plateaued. For example, if these figures hold, they would represent the broadest degree of outsourcing for analytical testing of bioassay services since 2011.

    Outsourcing of testing services, operations activities growing
    One of the notable trends to appear from this year’s preliminary data is the growing share of respondents that are outsourcing testing services. This trend is not limited to testing of bioassays as outlined above—which saw a hefty increase in its own right. In fact, other testing services are also seeing concurrent increases, including:
    • Product characterization testing (69%, up from 62.1% last year);
    • Cell line stability testing (65% outsourcing, up from 56%); and
    • Testing of host cell protein analysis (59%, up from 41%).
    Beyond testing services, another noteworthy result is the degree to which some of the traditionally lesser-outsourced activities are experiencing an increase in adoption. This extends to high-value production operations and even quality by design (QbD). For example, our preliminary data indicates that:
    • Almost half (49%) of respondents reported outsourcing at least some upstream production operations, up from 42% last year and more than double the 21% from 2010;
    • 46% are now outsourcing some downstream production operations, up from 39% last year and 28% in 2010; and
    • Almost 45% are outsourcing QbD services, up from 38% last year and 19% in 2010.
    Fill-finish remains most heavily outsourced activity
    Fill-finish operations are the most heavily outsourced activity. To determine the percentage of an activity being outsourced, we looked at the degree to which respondents are outsourcing these various activities and estimated a percentage share based on the results.
    This year our preliminary data confirm the relatively high extent to which fill-finish operations are being outsourced: we estimate that almost two-fifths (39%) of all industry fill-finish activities are being outsourced. Although a much larger percentage of facilities, by number, outsource, by volume the larger facilities still retain in-house activities.  So the 39% volume is not unexpected.  This high-value activity is undertaken at the final stages where the drug product is highest, and a failure would represent a major risk. 

    Fill-finish perennially tops outsourcing lists, and they represent the highest level of fill-finish outsourcing yet. This result aligns with separate data from last year’s study, in which fill-finish manufacturers said that outsourcing of these activities to CMOs is one of the largest trends they’re seeing today in the fill-finish market.

    Following distantly is analytical testing of bioassays, of which we estimate 29% being outsourced, up slightly from last year’s 27% and in line with prior years. Toxicity testing follows, with more than one-quarter (26%) of these activities being performed by contracting organizations. 

    Compared to recent years, our preliminary data suggests a rebound in the degree to which some activities are being outsourced, including: host cell protein analysis testing; GMP training; early (pre-clinical) research; upstream production operations, upstream process development, and QbD services. Indeed, the latter two activities could be seeing their highest levels of outsourcing yet, although they remain at low levels.

    Overall, the activities that are seeing the smallest levels of outsourcing are:
    • Downstream process development  – 7.8% of all activities;
    • QbD services – 8.2%; and
    • Design of experiments (DoE) – 8.5%.
    Expect more outsourcing of API biologics manufacturing
    One activity that appears to be trending up in recent years is API biologics manufacturing. This year our estimates suggest that one-fifth (20%) of this activity is being outsourced, a figure that would represent the highest in our survey’s history and a marked increase from 8% in 2010.

    The data indicates that the companies engaging in outsourcing of this activity are doing so to a considerable degree. For example, some 59% of respondents report outsourcing at least some API biologics manufacturing activities, and an equal percentage say they’re outsourcing at least some GMP training. However while more than one-fifth of API biologics manufacturing is outsourced, less than one-eighth (11.5%) of GMP training is being outsourced (the fact that nearly 90% of training is being done ad hoc, in-house is a subject of future articles).

    The increase in API biologics manufacturing suggests that respondents are keeping to the projections. In recent years this area has been one of the top areas tabbed for future increases in outsourcing. For example, two years ago roughly 1 in 5 (20.8%) of respondents said that they would be outsourcing API biologics manufacturing at “significantly higher levels” in the following 24 months. Since then, outsourcing has grown from an estimated 15% of total API biologics manufacturing activity to an estimated 20.2% this year. 

    That makes this year’s preliminary results all the more telling. Once again, API biologics manufacturing is near the top of the list in projected outsourcing increases. This time, about one-quarter (24.5%) of respondents expect to significantly increase their outsourcing of this activity over the next 24 months, which would represent the most bullish forecast so far this decade. We note that API outsourcing can be a major step and one that involves strategically shifting how facilities plan their biologics manufacturing pipeline, so change in this area is likely to occur slowly, if steadily.

    This result is also impressive when considering that few activities this year are being tabbed for greater increases than last year, and several could see their growth rates flattening. For example, the leading activity for future increases—analytical testing of bioassays—has been cited by 33% of respondents to-date, down from 41% last year. Other activities such as cell line development (8% forecasting increases, down from 15% last year).

    In addition to API biologics manufacturing, lot release testing is also prediction a considerable rise in future outsourcing projections, with about 1 in 7 (14%) this year forecasting a significant rise over the coming 24 months, compared to about 1 in 10 (11%) last year.

    Growth forecasts remain strong yet tempered
    Aside from analyzing specific outsourcing activities, our annual study also looks at the overall picture in terms of manufacturing systems. This provides an alternate view of the current and future health of outsourcing.

    Among respondents producing in mammalian cell culture, our preliminary data indicates that roughly 4 in 10 (41%) are currently performing all of their production in-house. In other words, about 4 in 10 are not engaging in any outsourcing, a slight step up from last year’s results (35%).

    Similarly, roughly 4 in 10 (42%) respondents to-date producing in microbial fermentation say they are keeping all their production in-house, compared with 39% last year.

    Fast-forward 5 years, though, and those figures are expected to change quite dramatically, particularly for microbial fermentation. In 5 years, just 19% of respondents expect to be performing all their microbial fermentation production in-house, less than half the proportion doing so this year.

    For mammalian cell culture, almost three-quarters (74%) of respondents so far expect to be outsourcing at least some of their production by 2021, up from 59% currently doing so.

    In both cases, the 5-year projection for outsourcing in these systems is a little lower than last year. This aligns with the afore-mentioned data showing that growth projections for specific outsourcing activities are mostly flat or even on the decline this year. That may simply be a reflection of outsourcing heading towards a plateau given its growth in recent years.

    Conclusion
    Preliminary results from our 13th annual study of the biopharmaceutical industry indicate that outsourcing continues to be a widespread and growing activity among the biomanufacturing community. Interestingly, while traditionally outsourced activities such as fill-finish operations and bioassay testing are seeing growth and nearing market saturation, more high-value activities including production operations and process development are also gaining steam.

    This year’s data suggests that biomanufacturers are increasingly turning to outsourcing partners for testing services, whether those be bioassay testing, product characterization testing, or cell line stability testing. Outsourcing of API biologics manufacturing also appears to be on an upswing, as the degree to which this activity is being outsourced has seen growth in recent years—with further increases forecast.

    At the same time, there are obvious limits to outsourcing’s growth. With outsourcing of activities such as bioassay testing services already performed by upwards of 80% of companies, there’s not much room for continued growth. Outsourcing expansion may instead come in areas such as QbD services, process development and production operations, as these are overwhelmingly performed in-house today. Even so, projections for significant increases over the next 24 months are rather muted in these areas, suggesting that companies —as one might expect—will tread cautiously when they approach outsourcing of high-value activities.

    Nevertheless, given historical data from our studies—and preliminary results from our latest research—it seems reasonable to suggest that somewhere around two-thirds—if not more—of companies involved in mammalian cell culture and microbial fermentation production will outsource at least some of these activities by the end of this decade. 


    References
    1. 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates, Inc. Rockville, MD., April 2015. www.bioplanassociates.com/12th


    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports. elanger@bioplanassociates.com; 301-921-5979; www.bioplanassociates.com
    Related Searches
    • CMO
    • pipeline
    • biologics manufacturing
    • outsourced
    Suggested For You
    Vetio Animal Health Vetio Animal Health
    Kemwell Provides Services for U.S. Trial Kemwell Provides Services for U.S. Trial
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Year-End Trends in Biopharma Contract Manufacturing Year-End Trends in Biopharma Contract Manufacturing
    Economics of In-House  Buffer Preparation Economics of In-House Buffer Preparation
    Bavarian Nordic Initiates Phase 2 Ebola Study Bavarian Nordic Initiates Phase 2 Ebola Study
    Mammalian Cell Culture Drug Substances Sell Sheet Mammalian Cell Culture Drug Substances Sell Sheet
    Outsourcing Budgets Continue to Shine
Outsourcing Budgets Continue to Shine
    MEI Doses First MDS Patient MEI Doses First MDS Patient
    Threshold Cancer Treatment Shows Safety Threshold Cancer Treatment Shows Safety
    Kamada Posts Preliminary Pediatric Diabetes Data Kamada Posts Preliminary Pediatric Diabetes Data
    Fujifilm Diosynth Opens New UK Facility Fujifilm Diosynth Opens New UK Facility
    Tolerx, GSK Diabetes Study Misses Endpoint
 Tolerx, GSK Diabetes Study Misses Endpoint


    Related Columns

    • A Potential “Marriage”

      A Potential “Marriage”

      Initiator companies and generics/CMOs working together.
      Emil W. Ciurczak, DoraMaxx Consulting 11.17.20

    • When Politics and Science Collide

      When Politics and Science Collide

      COVID-19 illustrates why science should always be a principal informer of politics to make better and smarter decisions.
      Ben Locwin, Contributing Editor 11.17.20

    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20


    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20

    • cGMP Manufacture
      Keys to Biotech Success

      Keys to Biotech Success

      Four steps emerging biotech companies can take to achieve success
      Thierry Cournez, Head of End-to-End Solutions, MilliporeSigma 06.04.20

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20


    • Almost Like the Olympics:

      Almost Like the Olympics:

      “Smaller, Faster, Smarter”
      Emil W. Ciurczak, DoraMaxx Consulting 05.05.20

    • Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Managing Editor, Contract Pharma 05.05.20

    • The Supply Chain House of Cards

      The Supply Chain House of Cards

      The COVID-19 pandemic exposes pressures on extended global supply chains
      Emil W. Ciurczak, DoraMaxx Consulting 04.01.20


    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Coronavirus 2020

      Coronavirus 2020

      What’s The Impact To The World and Industry?
      Ben Locwin, Contributing Editor 03.04.20

    • Supply Chain
      What We Have is Failure to Communicate

      What We Have is Failure to Communicate

      When it comes to implementing track and trace technology, why is Pharma dragging its feet?
      Emil W. Ciurczak, DoraMaxx Consulting 01.28.20


    • Vision: 2020

      Vision: 2020

      You have exactly 366 days in 2020 to bring your clarity of vision to reality.
      Ben Locwin 01.28.20

    • Solid Dosage/Creams/Ointments
      The “Greening” of Solid Dosage Form Manufacturing

      The “Greening” of Solid Dosage Form Manufacturing

      Going “green” can mean saving big bucks for pharma manufacturers.
      Emil W. Ciurczak, DoraMaxx Consulting 11.20.19

    • When Life Gives You Lemons…Raise Your Drug Prices

      When Life Gives You Lemons…Raise Your Drug Prices

      The hidden effect of economic models on global drug supply and shortages.
      Ben Locwin 11.20.19

    Trending
    • Fujifilm To Invest $2B In US Manufacturing Site
    • Baxter, Novavax Ink Sterile Manufacturing Agreement
    • A New Era Of Vaccine And Biologic Drug Development
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Roche Canada To Invest $500M To Create 500 Jobs In Ontario
    Breaking News
    • KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    • Frontage Bolsters Clinical Services Capabilities
    • Sanofi Unveils EUROAPI as Name of New European API Company
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • Precision Medicine Group Acquires Project Farma
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Brown Fat Associated with Reductions in Chronic Disease Risk
    NIH Study Identifies Antibacterial Properties in Taurine
    NSF Begins New Certification Program
    Coatings World

    Latest Breaking News From Coatings World

    Zeppelin Acquires MTI Mischtechnik
    Ezio Braggio Joins ChemQuest Europe
    IFS Coatings Announce Carbon Offset Program
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Optimize EP Launches CaRM Cardiac Device Data Management Platform
    U.S. TAVR Market Projected to Reach Nearly $5 Billion by 2030
    FDA Clears Canon Medical's Compressed SPEEDER for 3D Exams on 1.5T MR
    Contract Pharma

    Latest Breaking News From Contract Pharma

    KORSCH, MEDELPHARM Partner on R&D Equipment Portfolio
    Frontage Bolsters Clinical Services Capabilities
    Sanofi Unveils EUROAPI as Name of New European API Company
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Neenah to Host Packaging Webinar for Printers
    W.S. Badger is Named a ‘150 Top Impact Company’
    Mana Products, Meiyume and RPG Form The Vertical Beauty Alliance
    Happi

    Latest Breaking News From Happi

    A Surge in Interest for Supplements & Vitamins
    What You're Reading on Happi.com
    Three Form Vertical Beauty Alliance
    Ink World

    Latest Breaking News From Ink World

    dar-tech, inc. Becomes U.S. Midwestern Distributor for ZS Interpolymer
    Techkon USA, Konica Minolta Partner
    Alon Bar-Shany Appointed Chairman of Highcon Board
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Exhibitor registration opens for virtual.drupa
    FTA planning in-person Forum & INFOFLEX
    Fortis Solutions Group achieves SGP certification
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Shemesh Adds U.S. Headquarters
    TZMO USA, Special Needs Group Form Partnership
    BAHP Announces 2021 Officers, Board of Directors
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Rapid Recovery Protocol Can Lead to Increased Range of Motion After TKA
    Boston Scientific Releases WaveWriter Alpha Spinal Cord Stimulators in U.S.
    New Chief Clinical Officer on Board at IncludeHealth
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Toppan Announces 2050 Environmental Vision
    SOI Industry Consortium Joins SEMI as Strategic Association Partner

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login